David J Maloney

US Patent:

7605241, Oct 20, 2009

Filed:

Jan 10, 2006

Appl. No.:

11/794969

Inventors:

Sidney M. Hecht - Charlottesville VA, US
David J. Maloney - New York NY, US

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

C07G 3/00
C07H 17/00

US Classification:

536 185, 536 186, 536124

Abstract:

The synthesis of the naturally occurring kaempferol glycoside SLO1O1-1, as well as analogs thereof, has been accomplished, as has its biochemical evaluation. SLO1O1-1 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthetic scheme of the invention verified the structural assignment of the natural product and has provided access to material sufficient for detailed biological evaluation.

US Patent:

8426568, Apr 23, 2013

Filed:

May 22, 2007

Appl. No.:

12/301656

Inventors:

Jeffrey A. Smith - Earlysville VA, US
Sidney M. Hecht - Charlottesville VA, US
Deborah A. Lannigan-Macara - Charlottesville VA, US
David J. Maloney - Point of Rocks MD, US

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

C07H 17/07
A61K 31/7048

US Classification:

536 8, 514 27

Abstract:

The present invention provides compositions and methods useful for preparing and using analogs, derivatives, and modifications of kaempferols that have anti-neoplastic activity. More specifically, the compounds are analogs, derivatives, and modifications of SLO1O1. The invention further provides compounds that are inhibitors of rsk activity. The invention further provides compounds that selectively inhibit excessive rsk activity in cancers. The present invention further provides methods for treating cancer using compounds of the invention.

US Patent:

20110207784, Aug 25, 2011

Filed:

Aug 13, 2009

Appl. No.:

13/057667

Inventors:

Craig J. Thomas - Gaithersburg MD, US
David J. Maloney - Point of Rocks MD, US
Ahmed A. Sayed - Cairo, EG
Anton Simeonov - Bethesda MD, US
David L. Williams - Oak Park IL, US

Assignee:

DEPARTMENT OF HEALTH AND HUMAN SERVICES - BETHESDA MD
ILLINOIS STATE UNIVERSITY - Normal IL

International Classification:

A61K 31/4245
C07D 271/08
C07D 413/10
C07D 413/04
C07D 413/14
A61P 33/12

US Classification:

514364, 548125

Abstract:

The invention provides 1,2,5-oxadiazole-containing compounds of Formula (I), wherein R, A, and Rare as defined herein, that are useful in treating schistosomiasis. The invention also provides a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, and a method of treating schistosomiasis in a mammal.

US Patent:

20130096159, Apr 18, 2013

Filed:

May 18, 2011

Appl. No.:

13/698340

Inventors:

David J. Maloney - Point of Rocks MD, US
Theodore Holman - Santa Cruz CA, US
Ajit Jadhav - Chantilly VA, US
Anton Simeonov - Bethesda MD, US
Jerry L. Nadler - Norfolk VA, US
Michael Holinstat - Ardmore PA, US

Assignee:

The United States of America, as represented the Secretary Department of Health & Human Service - Bethesda MD
Thomas Jefferson University - Philadelphia PA
Eastern Virginia Medical School - Norfolk VA
The Regents of the University of California - Oakland CA

International Classification:

C07D 409/04
C07D 215/28

US Classification:

514314, 546167, 546175, 514311

Abstract:

Disclosed are inhibitors of human 12-lipoxygenase of Formula (I) or (II), wherein R, R, R, and Rare as defined herein, that are useful in treating or preventing a 12-lipoxygenase mediated disease or disorder, e.g., diabetes. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal.

US Patent:

20130123344, May 16, 2013

Filed:

Jan 22, 2013

Appl. No.:

13/747406

Inventors:

The United States of America, as Represented by the Secretary, Department of Health and Human Services - Bethesda MD, US
Yu Liang - Gaithersburg MD, US
Jodi Vogel - Bethesda MD, US
David J. Maloney - Point of Rocks MD, US
Anton Simeonov - Bethesda MD, US
Ajit Jadhav - Chantilly VA, US

Assignee:

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD

International Classification:

A61K 31/551
C07D 215/14
A61K 31/506
A61K 31/5377
A61K 31/47
A61K 31/496

US Classification:

514 44 A, 514312, 51425307, 514256, 5142352, 514218, 546170, 546174, 544363, 544333, 544128, 540575

Abstract:

Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I):wherein R, R, R, R, and Rare as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.

US Patent:

20220259200, Aug 18, 2022

Filed:

Mar 11, 2020

Appl. No.:

17/605469

Inventors:

- Cambridge MD, US
- Bethesda MD, US
David J. MALONEY - Point of Rocks MD, US
Shyh Ming YANG - Doylestown PA, US
Ajit JADHAV - Chantilly VA, US
Daniel Jason URBAN - Poolesville MD, US

International Classification:

C07D 471/04
C07D 413/14
A61P 35/00

Abstract:

The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.

US Patent:

20210128580, May 6, 2021

Filed:

Mar 6, 2018

Appl. No.:

16/491826

Inventors:

- St. Louis MD, US
- Bethesda MD, US
Amy Clark - St. Louis MO, US
Ajit Jadhav - Chantilly VA, US
David Maloney - Point of Rocks MD, US
Brandon Harvey - Parkville MD, US
Mark Henderson - Damascus MD, US

Assignee:

Washington University - St. Louis MO
The United States of America, As Represented by the Secretary, Department Health and Human Service - Bethesda MD

International Classification:

A61K 31/554
A61K 45/06
A61K 31/4178
C07K 14/605
A61K 31/4985
A61K 31/155
A61K 9/00

Abstract:

The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases.

US Patent:

20200223836, Jul 16, 2020

Filed:

Nov 15, 2019

Appl. No.:

16/685128

Inventors:

- Cambridge MD, US
- Bethesda MD, US
David J. Maloney - Point of Rocks MD, US
Shyh Ming Yang - Doylestown PA, US
Ajit Jadhav - Chantilly VA, US

International Classification:

C07D 413/04
C07D 413/14
C07D 401/04
C07D 471/04
C07D 471/10
C07D 239/84
A61P 39/00
C07D 239/95
C07D 401/14
C07D 403/04
C07D 417/14

Abstract:

The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.